KR20220084418A - 신경활성 스테로이드, 조성물, 및 그의 용도 - Google Patents

신경활성 스테로이드, 조성물, 및 그의 용도 Download PDF

Info

Publication number
KR20220084418A
KR20220084418A KR1020227019157A KR20227019157A KR20220084418A KR 20220084418 A KR20220084418 A KR 20220084418A KR 1020227019157 A KR1020227019157 A KR 1020227019157A KR 20227019157 A KR20227019157 A KR 20227019157A KR 20220084418 A KR20220084418 A KR 20220084418A
Authority
KR
South Korea
Prior art keywords
dose
subject
depression
compound
neuroactive steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227019157A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 제이 케인즈
헬렌 콜퀴훈
Original Assignee
세이지 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세이지 테라퓨틱스, 인크. filed Critical 세이지 테라퓨틱스, 인크.
Priority to KR1020247035389A priority Critical patent/KR20240157128A/ko
Publication of KR20220084418A publication Critical patent/KR20220084418A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
KR1020227019157A 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도 Ceased KR20220084418A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247035389A KR20240157128A (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201662305279P 2016-03-08 2016-03-08
US62/305,279 2016-03-08
US201662355174P 2016-06-27 2016-06-27
US62/355,174 2016-06-27
US201662355669P 2016-06-28 2016-06-28
US62/355,669 2016-06-28
US201662360762P 2016-07-11 2016-07-11
US201662360758P 2016-07-11 2016-07-11
US62/360,762 2016-07-11
US62/360,758 2016-07-11
PCT/US2017/021325 WO2017156103A1 (en) 2016-03-08 2017-03-08 Neuroactive steroids, compositions, and uses thereof
KR1020187028838A KR102408399B1 (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028838A Division KR102408399B1 (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247035389A Division KR20240157128A (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도

Publications (1)

Publication Number Publication Date
KR20220084418A true KR20220084418A (ko) 2022-06-21

Family

ID=59789807

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227019157A Ceased KR20220084418A (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도
KR1020247035389A Pending KR20240157128A (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도
KR1020187028838A Active KR102408399B1 (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247035389A Pending KR20240157128A (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도
KR1020187028838A Active KR102408399B1 (ko) 2016-03-08 2017-03-08 신경활성 스테로이드, 조성물, 및 그의 용도

Country Status (20)

Country Link
US (4) US20200306265A1 (cg-RX-API-DMAC7.html)
EP (1) EP3426257A4 (cg-RX-API-DMAC7.html)
JP (3) JP6838074B2 (cg-RX-API-DMAC7.html)
KR (3) KR20220084418A (cg-RX-API-DMAC7.html)
CN (2) CN109414444A (cg-RX-API-DMAC7.html)
AU (2) AU2017229656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018067998A2 (cg-RX-API-DMAC7.html)
CA (2) CA3158448A1 (cg-RX-API-DMAC7.html)
HK (1) HK1258616A1 (cg-RX-API-DMAC7.html)
IL (2) IL261658B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20170059B1 (cg-RX-API-DMAC7.html)
MA (1) MA43815A (cg-RX-API-DMAC7.html)
MX (2) MX391122B (cg-RX-API-DMAC7.html)
NZ (1) NZ785712A (cg-RX-API-DMAC7.html)
PH (2) PH12022551313A1 (cg-RX-API-DMAC7.html)
RU (2) RU2022102537A (cg-RX-API-DMAC7.html)
SG (1) SG11201807785VA (cg-RX-API-DMAC7.html)
TW (2) TWI798173B (cg-RX-API-DMAC7.html)
WO (1) WO2017156103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805905B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528485A (ja) 2011-10-14 2014-10-27 セージ セラピューティクス， インコーポレイテッド ３，３−二置換１９−ノルプレグナン化合物およびその使用
NZ773177A (en) 2012-01-23 2022-09-30 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9512165B2 (en) 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
ES2998982T3 (en) 2013-04-17 2025-02-24 Sage Therapeutics Inc 19-nor neuroactive steroids for inducing sedation
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
PT3021852T (pt) 2013-07-19 2021-04-21 Sage Therapeutics Inc Esteroides neuroativos, composições e utilizações das mesmas
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3158448A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
NZ749664A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, c20, and c21 substituted neuroactive steroids and their methods of use
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
EP3579842A4 (en) * 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
AU2018327357B2 (en) * 2017-09-07 2024-08-22 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019075362A1 (en) * 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
EA202091144A1 (ru) * 2017-11-10 2020-09-16 Маринус Фармасьютикалз, Инк. Ганаксолон для использования в лечении наследственных эпилептических заболеваний
EP4484440A3 (en) 2017-12-08 2025-03-26 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CN113999277B (zh) * 2018-02-11 2023-08-29 江苏豪森药业集团有限公司 甾族类衍生物调节剂、其制备方法和应用
CN112533611A (zh) * 2018-06-12 2021-03-19 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
EP3860595A4 (en) * 2018-11-05 2021-11-10 Ovid Therapeutics Inc. USE OF GABOXADOL, GANAXOLONE, AND ALLOPREGNANOLONE TO TREAT MOTION DISORDERS
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
WO2020118142A1 (en) * 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
TW202043204A (zh) * 2019-01-14 2020-12-01 中國大陸商北京軒義醫藥科技有限公司 四唑啉酮取代的類固醇化合物及其用途
US11497754B2 (en) 2019-02-05 2022-11-15 Washington University Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions
AU2020231506A1 (en) * 2019-03-04 2021-09-30 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause
KR20220006565A (ko) 2019-05-10 2022-01-17 브리 바이오사이언시스, 인크. 브렉사놀론, 가낙솔론, 또는 주라놀론을 함유하는 약제 조성물, 및 이것의 용도
KR20220016098A (ko) 2019-05-31 2022-02-08 세이지 테라퓨틱스, 인크. 신경활성 스테로이드 및 이의 조성물
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN119950517A (zh) * 2019-12-06 2025-05-09 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
MX2022008614A (es) * 2020-01-12 2022-10-10 Brii Biosciences Inc Esteroides neuroactivos y composicion farmaceutica que contiene los mismos.
CA3176854A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
EP4255438A4 (en) * 2020-12-07 2024-10-16 Marinus Pharmaceuticals, Inc. USE OF GANAXOLONE IN THE TREATMENT OF AN EPILEPTIC DISORDER
CN112516086B (zh) * 2020-12-08 2022-05-20 武汉久安药物研究院有限公司 注射用布瑞诺龙脂肪乳及其制备方法
WO2022165017A1 (en) * 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
BR112023021131A2 (pt) * 2021-04-12 2023-12-19 Sage Therapeutics Inc Tratamento de tremor essencial
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US11337987B1 (en) * 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders
US12208103B1 (en) 2021-05-07 2025-01-28 Lipocine Inc. Compositions and methods for treating CNS disorders
CA3226489A1 (en) 2021-07-28 2023-02-02 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
JP2025504069A (ja) * 2022-01-27 2025-02-06 ベルナップ ファーマシューティカルズ， エルエルシー オキシトシンを使用した治療方法
US20250170149A1 (en) * 2022-02-28 2025-05-29 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
US20250345345A1 (en) * 2022-04-26 2025-11-13 Praxis Precision Medicines, Inc. Methods for the treatment of neurological disorders
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2024059608A1 (en) * 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
CN115957332B (zh) * 2022-11-01 2023-10-10 北京华睿鼎信科技有限公司 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用
TWI897404B (zh) * 2023-05-11 2025-09-11 大陸商上海樞境生物科技有限公司 甾體類化合物、製備方法及其用途

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117142A (en) 1961-03-01 1964-01-07 Roussel Uclaf Novel preparation of estradiol and estrone
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
US3865939A (en) 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
WO1993005786A1 (en) 1991-09-13 1993-04-01 Cocensys, Inc. Novel gabaa receptor with steroid binding sites
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
NZ282939A (en) 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
WO1996003421A1 (en) 1994-07-21 1996-02-08 Pharmacia & Upjohn Company Neurologically active aminosteroids
AP653A (en) 1994-11-23 1998-07-21 Cocensys Inc Androstane and pregnane series for allosteric modulations of gaba receptor.
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
BR9608592A (pt) 1995-06-06 1999-06-29 Cocensys Inc Esteróides neuroativos da série do androstano e do pregnano
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US7630757B2 (en) 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
AU756001B2 (en) 1998-03-11 2003-01-02 Umecrine Mood Ab Epiallopregnanolone in the treatment of CNS disorders
US20020198174A1 (en) 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
WO2002064804A2 (en) 2001-02-13 2002-08-22 University Of Florida A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
WO2002094244A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of benzodiazepines through an inhalation route
WO2002094218A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
US9339508B2 (en) 2003-01-17 2016-05-17 Mapreg Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
WO2005000869A1 (en) 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
US7816074B2 (en) 2003-07-31 2010-10-19 The Research Foundation Of State University Of New York α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ATE497787T1 (de) 2004-03-12 2011-02-15 Cipla Ltd Sterilisationsprozess für steroide
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
JP2008530134A (ja) 2005-02-15 2008-08-07 エラン ファーマ インターナショナル リミテッド ナノ粒子ベンゾジアゼピンのエアロゾル製剤および注射用製剤
ATE499104T1 (de) 2005-03-24 2011-03-15 Univ Emory Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
NZ568700A (en) 2005-11-28 2012-03-30 Marinus Pharmaceuticals Solid stabilized particulate formulations comprising ganaxolone
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
MX2008014840A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US7813811B2 (en) 2007-02-08 2010-10-12 Neuropace, Inc. Refillable reservoir lead systems
AU2008240259C1 (en) 2007-04-11 2022-11-24 Biomarin Pharmaceutical Inc. Tetrahydrobiopterin compositions and methods of measuring
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US8969329B2 (en) 2007-06-11 2015-03-03 University Of Southern California Allopregnanolone in a method for enhancing neurological function
EP2155204B1 (en) 2007-06-15 2016-08-17 Research Triangle Institute Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
WO2009000038A1 (en) 2007-06-28 2008-12-31 Cnsbio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
BRPI0821970A2 (pt) 2008-01-03 2015-06-23 Biomarin Pharm Inc Análogos de pterina para tratamento de condição responsiva a bh4
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
CZ301216B6 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
PL2356109T3 (pl) 2008-10-10 2017-07-31 Vm Discovery, Inc. Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób
CN102300566A (zh) 2008-11-30 2011-12-28 O·扎查尔 血管收缩剂的皮肤应用
WO2010075863A1 (en) * 2008-12-29 2010-07-08 University Of Tartu (Tartu Ülikool) Arginase inhibitors for the treatment of depression
WO2010088409A2 (en) 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US20120142645A1 (en) 2009-03-17 2012-06-07 Marx Christine E Neuroactive steroid compositions and methods of use for lowering cholesterol
CZ303037B6 (cs) * 2009-05-28 2012-03-07 Ústav organické chemie a biochemie, Akademie ved CR, v. v. i. Deriváty pregnanolonu substituované v poloze 3alfa, zpusob jejich výroby a jejich použití
US20110152840A1 (en) * 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
EP2525798B1 (en) 2010-01-21 2017-08-09 Drawbridge Pharmaceuticals Pty Ltd. Anaesthetic formulation
CN103313744B (zh) 2010-11-03 2015-06-10 赛诺菲-安万特德国有限公司 容纳药物的针插管
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
WO2012116290A2 (en) 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
JP5893135B2 (ja) 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
CA2843436A1 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
RS64332B1 (sr) 2011-09-08 2023-08-31 Sage Therapeutics Inc Neuroaktivni steroidi, kompozicije i njihova upotreba
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
JP2014528485A (ja) 2011-10-14 2014-10-27 セージ セラピューティクス， インコーポレイテッド ３，３−二置換１９−ノルプレグナン化合物およびその使用
CA2856599C (en) 2011-11-29 2017-05-30 Amino Up Chemical Co., Ltd. Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function
NZ773177A (en) 2012-01-23 2022-09-30 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
EP2887944B1 (en) * 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
WO2014058736A1 (en) 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2916846B1 (en) 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
AU2013352141B2 (en) * 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
CN105026415B (zh) 2012-12-18 2019-02-01 华盛顿大学 神经活性的19-烷氧基-17-取代的甾族化合物、其前药以及利用所述化合物的治疗方法
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
ES2998982T3 (en) 2013-04-17 2025-02-24 Sage Therapeutics Inc 19-nor neuroactive steroids for inducing sedation
US9512165B2 (en) 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
PT3021852T (pt) 2013-07-19 2021-04-21 Sage Therapeutics Inc Esteroides neuroativos, composições e utilizações das mesmas
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
MX394493B (es) * 2014-05-29 2025-03-24 Sage Therapeutics Inc Esteroides neuroactivos, composiciones, y usos de los mismos
WO2015195962A1 (en) * 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
JP2018504420A (ja) 2015-02-06 2018-02-15 マリナス ファーマシューティカルズ インコーポレイテッド 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
GB2541015A (en) 2015-08-06 2017-02-08 Ge Oil & Gas Uk Ltd Subsea flying lead
AU2016338916B2 (en) 2015-10-14 2021-12-23 The Regents Of The University Of California Enhancing beta cell replication and/or survival
CA3158448A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPLEPTIC DISORDERS
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
US20180050107A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Neurosteroid compositions and methods of use thereof
US10098895B2 (en) 2016-09-07 2018-10-16 Glia, Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018169798A1 (en) 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
CA3060255A1 (en) 2017-04-18 2018-10-25 Marinus Pharmaceuticals, Inc Sustained release injectable neurosteroid formulations
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US11752115B2 (en) 2017-06-21 2023-09-12 The Board Of Trustees Of The University Of Illinois PPAR-alpha agonist treatment of neuropsychiatric disorders
US11266663B2 (en) 2017-06-23 2022-03-08 The Board Of Trustees Of The University Of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
JP7557185B2 (ja) 2017-06-23 2024-09-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫応答を調節するｇａｂａの能力の強化
EA202091144A1 (ru) 2017-11-10 2020-09-16 Маринус Фармасьютикалз, Инк. Ганаксолон для использования в лечении наследственных эпилептических заболеваний
UY38213A (es) 2018-05-04 2019-10-31 Acerus Pharmaceuticals Corp Derivados de neuroesteroides y usos de estos
JP2022506944A (ja) 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス，インコーポレーテッド ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
CN113365635A (zh) 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途

Also Published As

Publication number Publication date
US11554125B2 (en) 2023-01-17
JP6838074B2 (ja) 2021-03-03
US20200171049A1 (en) 2020-06-04
NZ745870A (en) 2025-03-28
RU2766155C2 (ru) 2022-02-08
WO2017156103A1 (en) 2017-09-14
CA3017172A1 (en) 2017-09-14
RU2018135079A (ru) 2020-04-08
HK1258616A1 (zh) 2019-11-15
EP3426257A4 (en) 2019-11-13
MA43815A (fr) 2021-04-07
RU2022102537A (ru) 2022-03-30
TWI798173B (zh) 2023-04-11
US20220023313A1 (en) 2022-01-27
IL261658B2 (en) 2023-07-01
ZA201805905B (en) 2019-07-31
CN109414444A (zh) 2019-03-01
PH12022551313A1 (en) 2024-06-24
AU2017229656A1 (en) 2018-10-11
SG11201807785VA (en) 2018-10-30
IL300422A (en) 2023-04-01
US10940156B2 (en) 2021-03-09
AU2022283769A1 (en) 2023-02-02
CA3158448A1 (en) 2017-09-14
KR20180115797A (ko) 2018-10-23
EP3426257A1 (en) 2019-01-16
US20230355639A1 (en) 2023-11-09
MX391122B (es) 2025-03-19
US20200306265A1 (en) 2020-10-01
IL261658B1 (en) 2023-03-01
JOP20170059B1 (ar) 2021-08-17
NZ785712A (en) 2025-03-28
BR112018067998A2 (pt) 2019-04-16
JP2023093723A (ja) 2023-07-04
CN113616661A (zh) 2021-11-09
MX2022003896A (es) 2022-04-19
TW202400182A (zh) 2024-01-01
RU2018135079A3 (cg-RX-API-DMAC7.html) 2020-04-16
KR20240157128A (ko) 2024-10-31
CA3017172C (en) 2023-03-14
AU2022283769B2 (en) 2025-03-06
JP2021073309A (ja) 2021-05-13
TW201733592A (zh) 2017-10-01
JP2019511488A (ja) 2019-04-25
PH12018501923B1 (en) 2024-06-28
MX2018010902A (es) 2019-03-06
IL300422B1 (en) 2025-11-01
KR102408399B1 (ko) 2022-06-13
IL261658A (en) 2018-10-31
AU2017229656B2 (en) 2022-09-29
PH12018501923A1 (en) 2019-07-01

Similar Documents

Publication Publication Date Title
KR102408399B1 (ko) 신경활성 스테로이드, 조성물, 및 그의 용도
US20250213591A1 (en) Neuroactive steroids, compositions, and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220607

Application number text: 1020187028838

Filing date: 20181005

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220707

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220714

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230515

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240524

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230515

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20220714

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241023

Application number text: 1020187028838

Filing date: 20181005